Jianli Wang;雪涛 曹;Weiping Zhang;Tianxing Ye;Kenzaburo Tani
Second Military Medical University;The University of Tokyo
发表时间:1996-5
期 刊:Leukemia Research
语 言:English
U R L: http://www.scopus.com/inward/record.url?scp=0029973496&partnerID=8YFLogxK
The therapeutic effects of fibroblast-mediated human interferon-alpha (IFN-α) gene therapy, alone or in combination with Doxorubicin (Dox), a chemotherapeutic agent, on the human leukemia-bearing nude mice were investigated. An NIH3T3 fibroblast clone (NIH3T3-IFN-α+) secreting the highest level of human IFN-α+ was obtained from the human IFN-α gene-transfected fibroblasts. Three days after i.p. implantation of NIH3T3-IFN-α+ cells, a certain level of human IFN-α could be detected in the sera from the implanted mice. After the NIH3T3-IFN-α+ cells were implanted intraperitoneally into leukemia-bearing nude mice, the growth of leukemia was inhibited and the survival time of the leukemia-bearing mice was prolonged. The growth of leukemia was inhibited more obviously and the survival rate of the mice increased significantly when NIH3T3-IFN-α+ cells were implanted in combination with Dox. These results demonstrate that fibroblast-mediated human IFN-α gene therapy is effective in treating leukemia and may achieve a better therapeutic effect when combined with Dox.
医学与生命科学
Scopus度量
年份 | CiteScore | SJR | SNIP |
---|---|---|---|
1996 | |||
1997 | |||
1998 | |||
1999 | 0.508 | 0.467 | |
2000 | 0.514 | 0.535 | |
2001 | 0.539 | 0.601 | |
2002 | 0.687 | 0.669 | |
2003 | 0.825 | 0.774 | |
2004 | 0.857 | 0.788 | |
2005 | 0.832 | 0.737 | |
2006 | 0.971 | 0.758 | |
2007 | 1 | 0.728 | |
2008 | 0.87 | 0.662 | |
2009 | 0.962 | 0.763 | |
2010 | 0.777 | 0.696 | |
2011 | 3.5 | 0.963 | 0.876 |
2012 | 3.9 | 0.885 | 0.825 |
2013 | 4.7 | 1.072 | 0.806 |
2014 | 4.3 | 1.047 | 0.782 |
2015 | 4.5 | 1.049 | 0.796 |
2016 | 4.9 | 0.997 | 0.801 |
2017 | 4.6 | 1.063 | 0.787 |
2018 | 4.1 | 0.892 | 0.701 |
2019 | 4 | 0.78 | 0.64 |
2020 | 4.3 |
相似文献推荐